After presenting early Phase I data at ASCO, Clovis Oncology Inc. (NASDAQ:CLVS) got back more than four times the market cap it lost late last year when lead program CO-101 failed a pivotal Phase II trial.

"This demonstrates the importance of having more than one drug in your portfolio and, in particular, having drugs from different technology platforms," said President and CEO Patrick Mahaffy.